Novartis Entered into a Collaboration and License Agreement with Dunad to Develop Oral Targeted Protein Degrader Therapies
Shots:
- Dunad to receive $24M up front, equity investment, research funding & is eligible to receive ~$1.3B milestones along with royalties & will also be responsible for program execution up to lead optimization
- Novartis gets an exclusive option to develop and commercialize the product that emerges from the research programs directed against up to 4 drug targets. If Novartis exercises its option, it will lead the development, manufacturing & commercialization globally of small-molecule therapeutic products against the targets
- The agreement will utilize Dunad's platform to produce novel oral covalent & protein degrading small molecule therapies across multiple target classes
Ref: PR Newswire | Image: Novartis
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com